diabetes

A new study finds that people who stop taking GLP-1 weight-loss and diabetes drugs, such as Ozempic and Wegovy, may face an increased risk of heart attack and stroke. The findings suggest the cardiovascular benefits of these medications depend on continued use, raising questions about how patients should manage long-term treatment.

India has proposed banning junk food sales in school canteens and within 50 meters of school premises, a measure aimed at curbing rising obesity and diabetes rates among children. The proposal is part of broader tightening of food rules in schools, and it is drawing attention to concerns over children's health and the food industry's role in school environments.

The World Economic Forum argues that chronic disease should be treated as an economic problem as well as a health crisis, highlighting the strain long-term illness places on workforces, productivity and public finances. The framing suggests policymakers need to address conditions like diabetes and heart disease through economic policy, not just healthcare systems.

A functional medicine expert is cautioning that high doses of GLP-1 weight-loss and diabetes drugs may affect more than appetite, potentially disrupting other bodily processes beyond food cravings. The warning, reported by Fox News, adds to ongoing debate about the safety and long-term effects of medications such as Ozempic and Wegovy as their use continues to expand.

India's Supreme Court has rebuked the government over delays in setting a timeline for mandatory warning labels on packaged food products. The criticism puts pressure on authorities to move forward with front-of-pack labelling rules, a measure health advocates have long pushed for to combat rising rates of obesity, diabetes and other diet-related diseases in the country.

Researchers at Michigan Medicine report new findings on lipodystrophy, a rare disorder in which the body lacks proper fat tissue, showing how the condition affects overall health beyond fat distribution. The work highlights links between lipodystrophy and metabolic complications such as diabetes and fatty liver disease, offering clinicians a clearer picture of why patients face elevated risks and how care might be better targeted.

Major food companies in India are urging regulators to reconsider the red colour proposed for warning labels on packaged foods, Reuters reports. The industry argues the red symbol could stigmatise products, while health advocates support strong front-of-pack warnings to combat rising obesity, diabetes and high salt, sugar and fat consumption in the country.

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.

New coverage reports that heart and kidney complications in patients with type 2 diabetes increase as the disease progresses over time. The finding underscores the cumulative toll of diabetes on cardiovascular and renal health and highlights the importance of long-term monitoring and management of blood sugar, blood pressure and kidney function in affected patients.

Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.